SB-215505

SB-215505 is a drug which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor, with good selectivity over the related 5-HT2A and 5-HT2C receptors.[1] It is used in scientific research into the function of the 5-HT2 family of receptors, especially to study the role of 5-HT2B receptors in the heart,[2][3][4] and to distinguish 5-HT2B-mediated responses from those produced by 5-HT2A or 5-HT2C.[5][6][7]

SB-215505
Identifiers
IUPAC name
  • 6-chloro-5-methyl-N-quinolin-4-yl-2,3-dihydroindole-1-carboxamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H16ClN3O
Molar mass337.81 g·mol−1
3D model (JSmol)
SMILES
  • CC1=C(C=C2C(=C1)CCN2C(=O)NC3=CC=NC4=CC=CC=C43)Cl
InChI
  • InChI=1S/C19H16ClN3O/c1-12-10-13-7-9-23(18(13)11-15(12)20)19(24)22-17-6-8-21-16-5-3-2-4-14(16)17/h2-6,8,10-11H,7,9H2,1H3,(H,21,22,24)
  • Key:BPVGSWDWIRIUME-UHFFFAOYSA-N
 NY (what is this?)  (verify)

References
  1. Kantor S, Jakus R, Balogh B, Benko A, Bagdy G (August 2004). "Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505". British Journal of Pharmacology. 142 (8): 1332–42. doi:10.1038/sj.bjp.0705887. PMC 1575194. PMID 15265808.
  2. Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L (August 2004). "Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts" (PDF). Circulation. 110 (8): 969–74. doi:10.1161/01.CIR.0000139856.20505.57. PMID 15302781.
  3. Liang YJ, Lai LP, Wang BW, Juang SJ, Chang CM, Leu JG, Shyu KG (November 2006). "Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-kappaB in cardiomyocytes". Cardiovascular Research. 72 (2): 303–12. doi:10.1016/j.cardiores.2006.08.003. PMID 16962085.
  4. Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J (August 2008). "Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice". Hypertension. 52 (2): 301–7. doi:10.1161/HYPERTENSIONAHA.107.105551. PMID 18591460.
  5. Reavill C, Kettle A, Holland V, Riley G, Blackburn TP (February 1999). "Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist". British Journal of Pharmacology. 126 (3): 572–4. doi:10.1038/sj.bjp.0702350. PMC 1565856. PMID 10188965.
  6. Fletcher PJ, Grottick AJ, Higgins GA (October 2002). "Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding". Neuropsychopharmacology. 27 (4): 576–86. doi:10.1016/S0893-133X(02)00342-1. PMID 12377394.
  7. Fletcher PJ, Tampakeras M, Sinyard J, Higgins GA (December 2007). "Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test". Psychopharmacology. 195 (2): 223–34. doi:10.1007/s00213-007-0891-z. PMID 17673981.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.